Journal article
Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy
Diagnostics (Basel), Vol.12(4), 842
03/29/2022
DOI: 10.3390/diagnostics12040842
PMCID: PMC9030726
PMID: 35453890
Abstract
Ovarian cancer is the deadliest of all gynecologic malignancies claiming the lives of nearly 14,000 women in the United States annually. Despite therapeutic advances, the ovarian cancer mortality rate has remained stagnant since the 1980's. The molecular heterogeneity of ovarian cancers suggest they may be more effectively treated via precision medicine. Current guidelines recommend germline and somatic testing for all new epithelial ovarian cancer diagnoses to assist providers in identifying candidates for targeted therapies. Next generation sequencing (NGS) identifies targetable, driver, and novel mutations used to guide treatment decisions. Performing NGS is standard of care in many other malignancies, but for ovarian cancer the use of NGS in daily practice is still emerging. This review discusses the targetable genetic mutations and role of NGS and molecular biomarker testing in the treatment of ovarian cancer.
Details
- Title: Subtitle
- Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy
- Creators
- Laura M. Harbin - University of KentuckyHolly H. Gallion - Markey Cancer CenterDerek B. Allison - University of KentuckyJill M. Kolesar - University of Kentucky
- Resource Type
- Journal article
- Publication Details
- Diagnostics (Basel), Vol.12(4), 842
- Publisher
- Mdpi
- DOI
- 10.3390/diagnostics12040842
- PMID
- 35453890
- PMCID
- PMC9030726
- ISSN
- 2075-4418
- eISSN
- 2075-4418
- Number of pages
- 17
- Language
- English
- Date published
- 03/29/2022
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695802902771
Metrics
4 Record Views